Literature DB >> 30957586

Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review.

Erica B Lee1, Kelly A Reynolds2, Deeti J Pithadia3, Alexander Egeberg4, Jashin J Wu5.   

Abstract

Entities:  

Year:  2019        PMID： 30957586     DOI： 10.1080/09546634.2019.1605133

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


× No keyword cloud information.
  1 in total

1.  Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.

Authors:  Christopher T Ritchlin; Philip S Helliwell; Wolf-Henning Boehncke; Enrique R Soriano; Elizabeth C Hsia; Alexa P Kollmeier; Soumya D Chakravarty; Federico Zazzetti; Ramanand A Subramanian; Xie L Xu; Qing C Zuraw; Shihong Sheng; Yusang Jiang; Prasheen Agarwal; Bei Zhou; Yanli Zhuang; May Shawi; Chetan S Karyekar; Atul Deodhar
Journal:  RMD Open       Date:  2021-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.